Targeting E-selectin to Tackle Cancer Using Uproleselan

E-selectin is a vascular adhesion molecule expressed mainly on endothelium, and its primary role to facilitate leukocyte cell trafficking by recognizing ligand surface proteins. gained new since it was demonstrated be involved in cancer trafficking, stem-like properties therapy resistance. Therefore, being the tumor microenvironment, can potentially used eradicate cancer. Uproleselan (also known as GMI-1271), specific antagonist, has been tested leukemia, myeloma, pancreatic, colon breast cells, most of which involve bone marrow or metastatic site. This novel disrupts microenvironment affecting two main steps metastasis—extravasation adhesion—thus blocking reduces dissemination. Additionally, uproleselan mobilized cells from protective niche into circulation, making them more susceptible chemotherapy. Several preclinical clinical studies summarized herein demonstrate that favorable safety pharmacokinetics microenvironment-disrupting agent improves efficacy chemotherapy, side effects such neutropenia, intestinal mucositis infections, extends overall survival. review highlights critical contribution uproleselan, regulation growth, dissemination, drug resistance context microenvironment.